Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations

查看全文 作　　者：Qin [1]Hu;Panpan [1]Hao;Qiji [2]Liu;Mei [1]Dong;Yaoqin [2]Gong;Cheng [1]Zhang;Yun [1]Zhang

机构地区：[1]The Key Laboratory of Cardiovascular Remodeling and Function Research, Ministry of Education of China, Ministry of Health of China and Chinese Academy of Medical Sciences, and The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital of Shandong University, Jinan 250012, China;[2]Department of Medical Genetics, School of Medicine, Key Laboratory of Experimental Teratology, Ministry of Education, Shandong University, Jinan 250012, China

出　　处：《Science China(Life Sciences)》索引2019年第62卷第6期,共13页

基　　金：supported by the State Key Program of National Natural Science of China (81530014);the National Natural Science Foundation of China (81370410, 81425004, 81770442, 81571689);the Taishan Scholars Program of Shandong province, China 摘　　要：Epidemiological research has revealed a galaxy of biomarkers, such as genes, molecules or traits, which are associated with increased risk of atherosclerotic cardiovascular diseases(ASCVD). However, the etiological basis remains poorly characterized.Mendelian randomization(MR) involves the use of observational genetic data to ascertain the roles of disease-associated risk factors and, in particular, differentiate those reflecting the presence or severity of a disease from those contributing causally to a disease. Over the past decade, MR has evolved into a fruitful approach to clarifying the causal relation of a biomarker with ASCVD and to verifying potential therapeutic targets for ASCVD. In this review, we selected high-quality MR studies on ASCVD, examined the causal relationship of a series of biomarkers with ASCVD, and elucidated the role of MR in validating biomarkers as a therapeutic target by comparing the results from MR studies and randomized clinical trials(RCTs) for the treatment of ASCVD. The good agreement between the results derived by MR and RCTs suggests that MR could be performed as a screening process before novel drug development. However, when designing and interpreting a MR study, the assumptions and limitations inherent in this approach should be taken into account. Novel methodological developments, such as sensitivity analysis, will help to strengthen the validity of MR studies. 关键词：Mendelian RANDOMIZATION ATHEROSCLEROTIC CARDIOVASCULAR disease CAUSALITY THERAPEUTIC target

相关文献

参考文献（94）
引证文献（4）
耦合文献（79）

参考文献(94)

引证文献(4)

耦合文献(79)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations

参考文献(94)

引证文献(4)

耦合文献(79)

用户提示